Cellerant Therapeutics
Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerant’s romyelocel-L is a universal cell therapy which does not require HLA matching intended to prevent bacterial and fungal infections during neutropenia. In a randomized, controlled Phase 2 clinical trial in AML patients, romyelocel-L reduced infections and days in hospital. Cellerant is developing two novel antibody drug-conjugate (ADC) products: CLT030 to treat AML by selectively targeting and killing leukemic stem and blast cells, and CSC012-ADC for hematologic malignancies and solid tumor indications.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
17
11 to 50 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Cellerant Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
Showing 1 of 2 verified contacts
Top roles at Cellerant Therapeutics
2 distinct titles indexed · top 2 shown.
- 1associate process development scientist
- 1clinical data manager
Sign up to unlock all 2 contacts at Cellerant Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Cellerant Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.